MedTrace Logo

Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function

NCT03151239 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-07-14

No results posted yet for this study

Summary

The purpose of the study is to understand the effect of the dietary supplement "Nicotinamide mononucleotide" on metabolic health in people.

Conditions

  • Glucose Metabolism Disorders

Interventions

DIETARY_SUPPLEMENT

NMN supplement

Intervention will last at least 8 weeks in the form of two capsules (250 mg total).

OTHER

Placebo

Intervention will last at least 8 weeks in the form of two capsules.

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Samuel Klein, MD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2019-05-30
Completion
2021-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03151239 on ClinicalTrials.gov